Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Anamorelin for Cancer-Associated Weight Loss and Anorexia in Advanced NSCLC
2018-002927-40Phase 3Completed
- Sponsor
- Helsinn
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC), cancer anorexia-cachexia syndrome (CACS) and cancer-associated anorexia comparing Anamorelin with Placebo (2 arms). Primary endpoint: Mean change in body weight from baseline over 12 weeks. Started Oct 2018; status: completed.
02
Drugs
anamorelin
03
Conditions
non-small cell lung cancer (NSCLC)cancer anorexia-cachexia syndrome (CACS)cancer-associated anorexia
Beyond the preview
Go deeper on 2018-002927-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002927-40.